PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform that has the potential to improve the absorption of many
drugs currently on the market and to reduce the risk of stomach
injury associated with certain drugs. The Company, with its lead
products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin
capsules (referred to together as “VAZALORE”), today provided a
VAZALORE launch update.
VAZALORE launch highlights include:
- Successfully supplied three stock
keeping units (“SKUs”) of VAZALORE into more than 30,000 retail
drugstores, supermarkets, mass merchandisers nationwide, and
e-commerce sites;
- Cardiovascular specialty field
force is expanding reach and increasing awareness among healthcare
professionals at leading heart/stroke hospitals and affiliated
clinical practices;
- Launched a national media
television campaign targeting providers and consumers;
- Received overwhelmingly positive
feedback from consumers and healthcare professionals;
- Major retailers have begun to place
VAZALORE in multiple locations within stores; and
- Aspirin remains an established
foundational therapy in practice guidelines for prevention of
another heart attack or clot-related stroke.
VAZALORE delivers aspirin differently from plain and enteric
coated aspirin products. The special complex inside the
capsule allows for targeted release of aspirin, limiting its direct
contact with the stomach. VAZALORE delivers fast, reliable
absorption for pain relief plus the lifesaving benefits of
aspirin.
The Company’s launch strategy for VAZALORE targets the over 40
million patients at risk of having another heart attack or stroke,
and diabetics who are at high risk for having such an event and
thus may be candidates for aspirin therapy under the guidance of
their physician.
“We are pleased with the initial launch of VAZALORE in major
retailers across the country. Supplying the inventory for such
extensive distribution, despite the challenging global market
dynamics associated with the pandemic and supply chain disruptions,
is a significant accomplishment,” stated Natasha Giordano, Chief
Executive Officer of PLx.
“As we continue to execute our launch plans and build brand
awareness for VAZALORE, our most important objective is to bring a
reliable and predictable aspirin therapy to the medical community
and to patients at risk for another heart attack or clot-related
stroke,” concluded Giordano.
Aspirin Guidelines
There has been some confusion in the media regarding the United
States Preventative Services Task Force (USPSTF) recommended
guidelines on the use of aspirin in prevention of cardiovascular
disease. The draft recommendations issued by the USPSTF pertain to
the use of aspirin for the prevention of a first cardiovascular
event, and do not pertain to those who have already had a
cardiovascular event, such as a heart attack or clot-related stroke
and are taking aspirin based on their doctor’s recommendation.
Several years ago, the American College of Cardiology and the
American Heart Association updated their recommendations to limit
the use of aspirin in patients without established cardiovascular
disease. Their recommendations, which are closely followed by
cardiologists, state that aspirin is an established practice for
the secondary prevention of a heart attack or clot-related
stroke.
Millions of people take aspirin daily as part of a
physician-recommended aspirin therapy plan. In addition, many
patients with a history of gastrointestinal (GI) issues reported
discontinuing aspirin therapy against medical advice because of
“stomach issues.”
VAZALORE delivers aspirin differently from plain and enteric
coated aspirin products. The special complex inside the
capsule allows for targeted release of aspirin, limiting its direct
contact with the stomach. VAZALORE delivers fast, reliable
absorption for pain relief plus the lifesaving benefits of
aspirin.
Conference Call
PLx management will host its third quarter 2021 conference call
as follows:
Date: |
Friday, November 12, 2021 |
Time: |
8:30 a.m. ET |
Toll free (U.S.): |
(866) 394-2901 |
International: |
(616) 548-5567 |
Webcast (live and replay): |
www.plxpharma.com under the ‘Investor Relations’ section. |
The archived webcast will be available for 30 days via the
aforementioned URL.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule,
available in 81 mg and 325 mg doses. VAZALORE delivers aspirin
differently from plain and enteric coated aspirin products. The
special complex inside the capsule allows for targeted release of
aspirin, limiting its direct contact with the stomach.
VAZALORE delivers fast, reliable absorption for pain relief
plus the lifesaving benefits of aspirin. To learn more about
VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma, Inc. is a specialty pharmaceutical company focused
on improving how active pharmaceutical ingredients (APIs) are
absorbed in the gastrointestinal (GI) tract via its clinically
validated and patent protected PLxGuard™ drug delivery platform.
PLx believes this platform has the potential to improve the
absorption of many drugs currently on the market or in development,
and to reduce the risk of stomach injury associated with certain
drugs. To learn more about PLx Pharma Inc. and its pipeline, please
visit www.plxpharma.com.
Forward-Looking Statements
Any statements made in this press release relating to future
financial or business performance, conditions, plans, prospects,
trends, or strategies and other financial and business matters,
including without limitation, the prospects for commercializing or
selling any products or drug candidates, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. In addition, when or if used in this press
release, the words “may,” “could,” “should,” “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and
similar expressions and their variants, as they relate to PLx may
identify forward-looking statements. PLx cautions that these
forward-looking statements are subject to numerous assumptions,
risks, and uncertainties, which change over time. Important factors
that may cause actual results to differ materially from the results
discussed in the forward-looking statements or historical
experience include risks and uncertainties, including the failure
by PLx to secure and maintain relationships with collaborators;
risks relating to clinical trials; risks relating to the
commercialization, if any, of PLx’s proposed product candidates
(such as marketing, regulatory, product liability, supply,
competition, and other risks); dependence on the efforts of third
parties; dependence on intellectual property, risks that PLx may
lack the financial resources and access to capital to fund proposed
operations. Further information on the factors and risks that could
affect PLx’s business, financial conditions and results of
operations are contained in PLx’s filings with the U.S. Securities
and Exchange Commission (“SEC”), which are available at
www.sec.gov. Other risks and uncertainties are more fully described
in PLx’s Form 10-K for the year ended December 31, 2020 filed with
the SEC on March 12, 2021, and in other filings that PLx has made
or will make going forward. The forward-looking statements
represent PLx’s estimate as of the date hereof only, and PLx
specifically disclaims any duty or obligation to update
forward-looking statements.
Contact Investor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
Source: PLx Pharma Inc.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024